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Background: Clinical research should provide reliable evidence to clinicians, health policy makers and
researchers, which is only possible once the results are made transparently available. The present
research aims to investigate factors in uencing publication rates, time and characteristics of clinical
trials on medicinal products and to assess the degree of accessibility of trial results on a country level.
Methods: Clinical trials authorized in Hungary in the year of 2012 were followed until publication and/or
June 2020. Corresponding scienti c publications were searched via clinical trial registries, Pubmed
(MEDLINE) and Google.
Results: Out of 330 clinical trials authorized in 2012, a total of 232 trials were completed for more than 1
year in June 2020. The proportion of industry-initiation was high (97%).
Time to publication was 21 (22) months [median (IQR)]. Time to publication was signi cantly shorter
when trials involved both European and non-European countries (p<0.001), and when registered in both
EU CTR and clinicaltrials.gov (p<0.001) based on survival analyses.
A signi cant amount (24.1%) of unpublished clinical trial results were accessible in a trial register. A total
of 70.93% of available publications were published “open access”.
Publications with domestic co-authors contribute to the research output of a country. In our study only
21.5% of the identi ed publications had a Hungarian author.
Conclusions: We encourage academic researchers to plan, register and conduct trials on medicinal
products. Registries should be considered as an important source of information of clinical trials results.
Measurable domestic scienti c impact of trials on medicinal products need further improvement.
Introduction
Clinical research should provide reliable evidence to clinicians, health policy makers and researchers (1),
which is only possible once the results are made publicly available (2). On a national level, published
research means that the resources expended are not waisted and the results of the research become part
of the international medical knowledge. Published research with a domestic author contributes to the
assessment of the scienti c performance of a country.
As of 2014, any trial of any medicinal product conducted in a member state of the European Union (EU) is
required to be registered in the European Union Clinical Trials Register (EU CTR), which is administered by
the European Medicines Agency (EMA). Following the 2012 European Commission guideline
2012/c302/03, sponsors must ensure that all trials registered on EU CTR disclose their results to the EMA
within 12 months of trial completion; phase I trials are exempt unless they are part of a pediatric
investigation plan (3). Voluntary initiatives (4) and recommendations (5) started to emphasize the
importance of registration of clinical trials and subsequent reporting of results. The EU CTR also tries to
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increase awareness on mandatory posting of results (6), and recently launched a page with a tutorial to
facilitate posting of results on the EU CTR webpage (7).
Beyond mandatory posting in EU CTR, European researchers also often make the decision to register their
studies in clinicaltrials.gov, the largest trial register worldwide. However, the extent to which trials
conducted in the EU are registered in clinicaltrials.gov and whether this “multiple registration” has
bene ted the reporting of trial results or scienti c quality of publications is not well investigated.
Results posted in registries currently have limited impact and awareness in the scienti c community.
Advantage of results reported to a registry is undeniably their standardized format (8, 9); however, these
results do not undergo rigorous evaluation as do full scienti c publications during the peer review
process. Besides, publications and scientometrics are – despite international initiatives to change this
(10) – currently an integral part of research evaluation and play a crucial role in decision making for
national research policies, funding, promotions, and the careers of scientists (7). Therefore, it should be
underlined that results posted in registries do not contribute to the total research output of either the
participating researchers nor the participating country.
The aim of this methodological cohort study was to investigate how and to what extent does an
authorized medical research conducted in a given country become visible and affects the research output
of that country. We investigated publication rates, time until publication and the relationship between
posting results in trial registers and publishing them as a full scienti c publication. Further, we aimed to
identify trial characteristics which are associated with timely publication of trial results, measures of
scienti c impact, authorship and open access publication in a representative sample of clinical trials
authorized in Hungary.
Methods
In order to examine the publication rates and time of clinical trials conducted in Hungary, we collected
detailed data on the human clinical trials on medicinal products authorized in the country back in 2012.
Search strategy
We used the advanced search function of the EU Clinical Trials Register (www.clinicaltrialsregister.eu) to
identify clinical trials registered within the date range of January 1, 2012 to December 31, 2012 with
Hungary as a participating research center.
Inclusion and exclusion criteria
Clinical trials were eligible for our study if a) Hungary was a site of the clinical trial; b) they were
registered in the database by the National Institute of Pharmacy (Hungary) in the year 2012; c) no
restrictions were applied to the trial phase, trial status or participant characteristics (e.g. age, gender,
disease group).
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Identi cation of trials in clinicaltrials.gov and data
extraction from registries
We tried to identify included trials in the register clinicaltrials.gov by searching the EU CTR identi er or by
the use of speci c PICO terms.
We extracted pre-de ned study characteristics from the study registries: full title of the trial, authorization
date, trial start and completion dates, information on participating countries, sponsor, funder, trial scope,
trial design, blinding, sample size, study phase, therapeutic area and presence of a data monitoring
committee (DMC).
We determined whether or not study results were available in the study registries EU Clinical Trial Register
and ClinicalTrials.gov. In this current paper, we aim to distinguish results available in the registries
(“results in registries”) from results published as full scienti c publications (“publication”).
Identi cation of corresponding scienti c publications
Full scienti c publications were de ned as publications which were published in a scienti c journal of
any type and were reporting study results on pre-de ned outcomes. We excluded methods papers and
published protocols, and publications which reported results of a secondary analysis.
The availability of scienti c publications was  rst checked in February 2019 and then 16 months later in
June 2020. Publications were identi ed in a step by step process for each trial. First, we checked whether
publications were already added to the register. In a second step, we searched for publications in the
PubMed database with the following identi cation data: a) the trial register number, b) the investigators’
names, c) keywords describing the intervention or the condition (PICO elements). As a third step, Google
was searched with the same search terms.
All identi ed publications, potentially belonging to the registered study were checked for their content
(study design, population characteristics, dates of recruitment, intervention, comparator). Publications
which clearly described the results of the originally planned and registered study were included.
Data extraction from scienti c publications
We extracted the following data from the scienti c publications: the presence of author(s) with a
Hungarian a liation; the number of Hungarian authors or whether Hungarian participation in the study
was mentioned in a way other than author a liation; the journal’s name, and date of publication. In cases
when there were different forms of publishing (e.g. published electronically ahead of print), we took the
 rst date when the full text of the  nal manuscript was accessible.
To estimate the time to publication, we counted total months between trial end date available in the EU
Clinical Trials Register and the publication date. We expressed publication rate as the percentage of
clinical trials with a full scienti c publication divided by all clinical trials. The number of all clinical trials
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was calculated separately for each month after trial completion, by adding trials without any publication
to the number of trials with a publication only until the elapsed time since their completion.
Impact factors for each journal were derived from the Journal Citation Report, Clarivate Analytics via
www.webofknowledge.com. Scimago journal rank (Q1-Q4) was derived from www.scimagojr.com.
We also wanted to see the public’s degree of accessibility of results from published scienti c
publications. We therefore investigated whether scienti c publications were published openly or with
closed access. No distinctions were made between publications published in an open access journal and
publications published in a hybrid journal by using the open access option.
Statistical analysis
For binary data, results were summarized as frequencies and proportions, and for continuous data as
medians and interquartile ranges. We considered three analysis sets: a dataset based on all trials
authorized in 2012 in Hungary, a dataset based on the trials completed for more than one year in June
2020, and a dataset based on corresponding publications. Data was analyzed by descriptive statistics
and cross-tabulation. Time to publication was estimated by the nonparametric Kaplan-Meier estimator
and the logrank test (by Mantel-Cox) was used to estimate potential effects of investigated factors on
time to publication. Hazard ratios and con dence intervals were calculated on the basis of a Cox




A total of 614 clinical trials were identi ed in our search. After excluding trials where 2012 did not
correspond to the Hungarian registration date, but to the registration date of another participating country
of multinational trials, a total of 330 Hungarian national or international clinical trials were eligible to be
included in our methodological cohort (see Additional File 1). Eight years after trial authorization (in June
2020), a total of 232 clinical trials were “completed” trials for at least 1 year. Baseline characteristics of
these trials are presented in Table 1.
Most of the trials were international, initiated and funded by the industry and assessed both e cacy and
safety of a therapeutic intervention. Of the investigated clinical trials, 91.8% were registered both in the EU
Clinical Trials Register and the clinicaltrials.gov database.
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Table 1
Baseline characteristics of investigated studies
  All trials authorized in
2012
(n = 330)
Trials authorized in 2012 and

































- Respiratory tract diseases
- Nervous system diseases
- Cardiovascular diseases
- Nutritional and metabolic
diseases























- registered in EU-CTR only 10.30 8.19
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  All trials authorized in
2012
(n = 330)
Trials authorized in 2012 and







Publication rate over time is shown in Fig. 1.
Twelve months after completion, 19.8% of clinical trials were published as full scienti c publication, while
5 years after trial completion 19.4% of studies were not available as full publication. The time between
the end of the clinical trial and the publication of the full scienti c paper was 21 (22) months [median
(IQR)].
At the time of our search, 74.1% of completed clinical trials had an available corresponding scienti c
publication. A total of 70.7% of trial results were available as both full scienti c publications and posted
in registries; 3.4 % as publications without posted results in registries, 24.1 % in registries without an
available full scienti c publication, and 1.7 % of the trials authorized in 2012 and completed for more
than one year had no results available in 2020 (see Additional File 2).
Factors in uencing time to publication
Time to publication was signi cantly shorter in case of trials involving countries from both inside and
outside Europe compared to trials with European sites only (Additional File 3; log rank p < 0.001); and in
case of trials registered in both EU CTR and clinicaltrials.gov compared to trials registered in EU CTR only
(Additional File 4; p < 0.001). Time to publication was not in uenced by either being a national or an
international trial (Additional File 5; p = 0.45), an RCT or non-RCT (Additional File 6; p = 0.56), or by the
presence or lack of a DMC (Additional File 7; p = 0.28) (Table 2).
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Table 2
Predictors of time to publication
  HR (95%CI) p
Trial sites
only Europe 1  
also from outside Europe 0.38 (0.22–0.66) 0.001
Trial registration
in EU CTR only 1  
EU CTR and clinicaltrials.gov 0.24 (0.11–0.54) 0.001
Participating countries
National 1  
International 0.65 (0.21–2.04) 0.46
Trial design
RCT 1  
non-RCT 1.12 (0.75–1.68) 0.57
DMC
No 1  
Yes 0.85 (0.63–1.15) 0.29
Scienti c results were published earlier, if published in a Q1 as compared to a Q2-Q3 journal (Fig. 2; log
rank p = 0.001; HR [95%CI]: 2.14 [1.32–3.48], p = 0.002).
Measures of scienti c impact
Hungarian authorship and participation
Hungary was mentioned in 48.0% of the scienti c publications (either as an author’s a liation or as a
study site listed in the text). Publications had at least one author with a Hungarian a liation only in
21.5% of cases (16.3% with one Hungarian author, 5.2% with two or more Hungarian authors).
Factors that signi cantly increased the probability of a scienti c publication with a Hungarian author
were trials conducted within Europe (RR 2.184 [1.104–4.321]) and initiated by the academy instead of the
industry (RR 3.706 [1.953–7.032]) .Other investigated factors, such as studies registered in EU CTR only
(0.769 [0.125–0.707), the lack of a DMC (1.071 [0.594–1.933]), non-RCT studies (1.216 [0.588–2.511]),
and national trial studies (1.565 [0.308–7.957) had no effect on Hungarian authorship.
Impact factor and Scimago ranking of the journal
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No differences were observed between the impact factor of publications with a Hungarian author
compared to publications without (IF16.02 [16.59] vs. 19.47 [23.89]; mean [SD]; p = 0.389). The impact
factor tended to be higher for international compared to national trials (18.98 [22.63] vs. 4.58 [4.48]; p = 
0.171), for trials conducted also outside from Europe as compared to trials within Europe (19.28 [22.77]
vs.12.47 [19.09]; p = 0.264), and for trials registered in both the clinicaltrials.gov and the EU CTR as
compared to trials registered in EU CTR only (19.08 [22.80] vs.8.92 [8.21]; p = 0.445).
Studies that were initiated by the industry were less likely to have their results published in a Q1 journal
(0.875 [0.826–0.926]), while trials with a data monitoring committee (DMC; i.e. a group of experts
external to the study monitoring safety during study conduct) were more likely (1.131 [1.008–1.270]).
Other investigated factors, such as registration in two or only one registry (1.055 [0.735–1.516]),
international versus national trial (2.663 [0.537–13.204]), trials conducted outside of versus within
Europe (1.249 [0.893–1.748]), or study design (1.020 [0.871–1.195]) did not affect the Scimago journal
ranking of the subsequent publication.
Study results available for all, as part of an open access
publication
A total of 70.93% of scienti c publications were openly accessible, making the results accessible to the
public. None of the investigated factors increased the probability for open access publication (see
Additional File 8).
In uence of the industry on transparency and scienti c
impact of a trial
The number of authorized clinical trials initiated by the academy was extremely low (2.7% of all




Role of industry in trial conduct: comparison between industry-initiated and academy-initiated clinical









Financial background    
Founded by the industry 96.88 11.11
Founded by non-industry 0 55.55
No information available 3.13 33.33
Trial design    
RCT 79.69 88.88
Non-RCT 16.88 11.11





Not clear 14.69 11.11
Collaboration    
National 1.88 44.44
International (only EEA) 88.75 33.33
International (within and outside the
EEA)
9.375 22.22
Trial scope    














Phase I 1.5625 0
Phase II 38.75 0
Phase III 52.8125 55.55
Phase IV 4.0625 22.22
Not mentioned/ More phases 2.8125 22.22
Data monitoring committee    
Yes 55.31 33.33
No 44.69 66.66
Availability of study results
Results posted in EU CTR 73.125 11.11
Results published as full scienti c
publication
62.8125 55.55
Time to publication (months; mean [SD]) 21.70 [16,82] 18.33 [3,77]
Impact on the scienti c reputation of the authorizing country






All industry-initiated trials with accessible information regarding funding were funded by the industry.
Investigator-initiated clinical trials were also partly funded by the industry. For one third of investigator-
initiated trials information on funding was unavailable.
A DMC was available to a much larger extent in trials initiated by the industry.
Results for investigator-initiated trials were signi cantly less likely to be posted in a clinical trial register
(73.1% vs. 11.1%) and also slightly less likely to be published as a full scienti c publication (62.8% vs.
55.6%).
Both the rate of publications with at least one Hungarian author (33.3% vs. 12.2%), and the rate of
publications mentioning Hungarian participation in any form (44.4% vs. 27.5) was higher among




Our study provides empirical evidence about the publication tendencies of authorized clinical trials in
Hungary, the impact of authorized clinical trials on the scienti c reputation of the authorizing country, and
the role of multiple registrations in increasing transparency.
A total of 97.3% of authorized and EU CTR -registered clinical trials were initiated by the industry. About
20% of clinical trials were published within one year after trial completion. Trials conducted only within
Europe and registered only in the EU CTR register were published signi cantly later.
Universality is a fundamental principle of science (11); open access publications have therefore the
largest impact on the scienti c community. In this study, 70.93% of publications were found to be openly
accessible to the public. However, we were not able to identify trial characteristics which might in uence
the access to scienti c publications.
Publications with Hungarian co-authors occurred in 21.5% of cases only. Clinical trials with study sites
within Europe and trials initiated by the academy resulted more often in scienti c publications with
Hungarian authors.
Trials registered not only in the EU Clinical Trials Register, but also in the clinicaltrials.gov database were
more likely to be identi ed as full publications. The results of clinical trials available as full scienti c
papers but absent in registries were in low numbers. However, we found that almost one quarter of results
of the investigated clinical trials were available in registries, but not as a full scienti c publication.
Strength and limitations of this methodological research
study
Our study analyzed a representative sample of trials authorized in Hungary, the results can therefore be
generalized to the country. All trials were registered in study registries, thus basic study information was
available for all the trials included in our study. All data extractors were trained and the main outcome
data were double-checked and double-extracted.
Our study has limitations. The cohort was composed of trials that were authorized and included in the
study registry EU Clinical Trials Register by the national authority. Due to the low number of investigator-
initiated trials it is di cult to draw  rm conclusions on their publication tendencies. Nevertheless, our
results may indicate a publication trend also for investigator-initiated trials.
Another limitation is, that the information provided for researchers in the EU Clinical Trials Register on
trials de ned as completed (when it „has been completed in accordance with the full requirements of the
protocol”) might be interpreted in different ways by researchers and may have impacted our results. We
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searched for scienti c publications in 2020 and trials completed within one year before the search date
were excluded.
Comparison with other studies
To our knowledge, this is the  rst study investigating how and to what extent research authorized and
conducted in a given country becomes visible and affects the scienti c performance of that country.
Authorship issues were already discussed is several papers, dealing mainly with gender distribution of
authorship (12, 13); association between sponsorship and authorship (14, 15); under-representation of
researchers from speci c regions in papers published from research done in these regions (16, 17); and
di culties and possibilities in determining authorship in multicenter clinical trials (18, 19). These studies
were mainly based on publication data sets. The approach to prospectively follow trials authorized in a
given country until publication and investigate authorship in such a cohort of studies is novel.
There was one large cohort study investigating compliance with requirement to report results on the EU
Clinical Trials Register up to December 2016 (8). This study found that trials with a commercial sponsor
tend to be substantially more likely to post results on the EU CTR than those with a non-commercial
sponsor (68.1% v 11.0%)(8). This is in line with the results of the present study: a signi cantly higher
posting of results in the EU CTR for industry-initiated trials were found (73.1%) than for investigator-
initiated trials (11.1%). Besides the need for standardized procedures (20), periodic quality control
assessments during trial implementation (21), improved reporting about funding (22), improvement of
reporting (23), mandatory trial registration and trial result posting are additional requirements which still
are not optimal in case of investigator-initiated trials.
Implications of  ndings for practice, policy and future
research
All interventional clinical trials on medicinal products authorized in the European Union and, without any
distinction by type of sponsor, should be registered in the EU Clinical Trials Register. To get a valid picture
about research activity on a country level, the EU Clinical Trial Register for trials conducted in Europe
should be the  rst step to register a trial. Trial registration in the clinicaltrials.gov register can further
increase the visibility of registered European trials.
The present research shows that a surprisingly low number of clinical trials initiated by the academy are
registered in the EU Clinical Trial Register in Hungary. Academic clinical trials have an important place on
the map of clinical research. These studies focus on speci c questions that arise during clinical care and
are extremely important in everyday medical practice; these include but are not limited to facilitating the
optimization of a therapy, or the discovery of potential new clinical areas where a therapeutic intervention
can be used. Increased transparency and use of results of academic clinical trials is essential for
evidence-based medical decision-making and optimal patient management.
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Posting trial results in study registries might be the  rst step to make study results become openly
available for the public; however, study results should be published also as a scienti c publication as
soon as possible after trial completion. Systematic reviewers and guideline developers are advised to
search clinical trial registers in addition to electronic databases to identify study results, which have not
been published as full text publications at the time of the search.
The present study also showed that the participation of Hungarian researchers in industry-initiated
studies on medicinal products has only partial measurable scienti c bene ts, as Hungarian researchers
appear as authors in only a fraction of scienti c publication derived from these trials. Several
publications not even contain the list of countries of trial participants. In line with the Lancet journals,
which strongly support the inclusion of authors from local countries on papers reporting studies from
those countries, we also would like to “encourage authors to include researchers who originally collected
the data, where possible, and to share expertise in analysis and other skills, so that the research capacity
of the country from which the data were obtained is strengthened” (24); i.e. to enable local researchers to
ful l the criteria for authorship developed by the International Committee for Medical Journal Editors.
The scienti c performance of universities and countries is evaluated and ranked – despite valuable
initiatives for change – based on research productivity (i.e. the number of scienti c publications),
research impact and research excellence (i.e. the number of scienti c papers in high impact journals).
Considering that slightly over a  fth of authorized Hungarian trials result in scienti c publications with a
Hungarian co-authorship, we can conclude that the authorized, mainly industry-initiated clinical trials on
medicinal products currently result in limited measurable scienti c bene ts to the participating
researchers and their countries.
Conclusions
We call researchers of investigator-initiated clinical trials, to register their trials in an openly available
clinical trial register. Trial registers have to be considered as an important source of information of
clinical trial results, as they may contain results from unpublished trials or trials published with closed
access. Domestic scienti c impact of trials on medicinal products has to be further improved; an increase
in the number and role of investigator-initiated trials might help to achieve this goal.
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Publication rates over time in a cohort of trials authorized in 2012 in Hungary (n=232)
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Figure 2
Publication rates over time in Q1 (n=151), and Q2-Q3 (n=21) journals* *the Q2-Q3 group contains 19 Q2
and two Q3 publications
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